FDA information request to delay Pargluva launch

Share this article:
The FDA has requested additional safety information before it can approve Bristol-Myers Squibb's potential blockbuster diabetes drug Pargluva (muraglitazar).
The request for more information could set back plans of BMS and Merck to market Pargluva for at least a year, according to analysts' estimates.
"The FDA has requested additional safety information from ongoing trials, or those completed since the safety data from the last formal regulatory submission, to address more fully the cardiovascular safety profile of Pargluva," the companies said in a joint statement.
Pargluva represents a new approach to treating Type 2 diabetes, the most common form of the disease. The drug could be the first FDA-approved product in the class known as dual peroxisome proliferators-activator receptor agonists, or PPAR.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.